Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225387 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
A Phase 4 study of Lupus Nephritis, sponsored by NephroNet.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT07225387 is a Phase 4 study of Lupus Nephritis that is actively recruiting participants, run by NephroNet. The registered enrollment target is 30 participants, below the 309-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT07225387, a Phase 4 study of Lupus Nephritis, is actively recruiting participants, sponsored by NephroNet.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.
Conditions Studied
Interventions
- DRUG Voclosporin
Study Locations (7)
Georgia
- Piedmont Physicians Rheumatology - Atlanta
- Georgia Nephrology Research Institute - Lawrenceville
- Parris & Associates - Lawrenceville
Arizona
- AARA Clinical Research - Glendale
Ohio
- Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center - Columbus
Oklahoma
- Oklahoma Medical Research Foundation - Oklahoma City
Texas
- AARA Clinical Research - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2027-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07225387
The ClinicalTrials.gov registry entry for NCT07225387 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 309-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (90% lower). The listed sponsor is NephroNet, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Voclosporin is the first listed.
NCT07225387 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Georgia, Arizona, Ohio.
Frequently Asked Questions
What is clinical trial NCT07225387 about?
NCT07225387 is a clinical study titled "Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial". This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) com...
What is the current status of trial NCT07225387?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-10-01. Estimated completion is 2027-01.
What conditions does trial NCT07225387 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT07225387?
The interventions under investigation include: Voclosporin (DRUG).
Who is sponsoring clinical trial NCT07225387?
This trial is sponsored by NephroNet, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07225387 being conducted?
This trial has 7 study locations across Arizona, Georgia, Ohio, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.